Thomas Michael Tamberrino Purchases 3,755 Shares of Profound Medical (TSE:PRN) Stock

Profound Medical Corp. (TSE:PRN) insider Thomas Michael Tamberrino acquired 3,755 shares of Profound Medical stock in a transaction dated Monday, August 17th. The shares were acquired at an average price of C$9.44 per share, with a total value of C$35,447.20. Following the completion of the purchase, the insider owned 53,573 shares in the company, valued at approximately C$505,729.12. The trade was a 7.54% increase in their ownership of the stock.

Profound Medical Price Performance

TSE:PRN opened at C$9.76 on Wednesday. The company has a debt-to-equity ratio of 14.82, a quick ratio of 14.98 and a current ratio of 6.46. The stock’s 50-day simple moving average is C$9.87 and its 200 day simple moving average is C$9.35. The company has a market cap of C$356.56 million, a P/E ratio of -9.86 and a beta of 1.30. Profound Medical Corp. has a 52-week low of C$5.23 and a 52-week high of C$12.40.

Profound Medical (TSE:PRN) last issued its quarterly earnings results on Thursday, August 6th. The company reported C($0.37) EPS for the quarter. The company had revenue of C$3.53 million for the quarter. Profound Medical had a negative net margin of 170.92% and a negative return on equity of 62.45%. As a group, sell-side analysts forecast that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Raymond James Financial raised shares of Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, July 27th. Eight analysts have rated the stock with a Buy rating, sixteen have assigned a Moderate Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of C$9.76.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.